Trial Profile
A Phase I Trial of Intratumoral Administration of CCL21-gene Modified Dendritic Cell (DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs CCL 21 (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2023 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
- 13 Jun 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 13 Sep 2022 Trial design presented at the 47th European Society for Medical Oncology Congress.